A Phase 2a Study of Brincidofovir in People With Cytomegalovirus Infection

Full Title

A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Brincidofovir in Subjects with Adenovirus Infection or Cytomegalovirus Infection

Purpose

Cytomegalovirus (CMV) is the most common infection that happens after someone receives a bone marrow transplant from a donor. In this study, researchers want to see how well  brincidofovir works in children and adults with CMV infection.

Brincidofovir releases a compound called cidofovir into the body. Cidofovir blocks the creation of DNA and the formation of viruses. By releasing cidofovir and blocking these processes, brincidofovir may stop CMV from continuing to infect your body. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You or your child must:

• Have CMV infection with a viral blood level of at least 500 IU/mL.
• Be age 2 months or older.

Contact

For more information or to see if you or your child can join this study, please call Dr. Genovefa Papanicolaou’s office at 212-639-8361.